ArticleClinical ophthalmology (Auckland, N.Z.)2025
Real-World Visual Outcomes and Rotational Stability of a Monofocal Toric Intraocular Lens.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Clinical performance of a segmented refractive multifocal IOL: visual outcomes, rotational stability, and the role of higher-order aberrations.International ophthalmology · 2026Article
- Intermediate Visual Performance of Clareon Versus Eyhance Enhanced Monofocal Intraocular Lenses.Diagnostics (Basel, Switzerland) · 2026Article
- Planning Adjustment of Toric Capsular Bag Intraocular Lens Axis to Minimise Refractive Cylinder Outcome-A Calculation Concept Based on Vergence Transformations.Diagnostics (Basel, Switzerland) · 2026Article
- Rotational Stability of the Clareon PanOptix Toric (CNWTTx) Hydrophobic Multifocal IOL: Real-World Clinical Outcomes.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess the real-world distance and intermediate visual outcomes, rotational stability, and adverse events (AEs) of patients implanted with a Clareon aspheric monofocal toric intraocular lens (IOL) preloaded in the AutonoMe delivery system (Alcon, USA; models CNA0T2 to CNA0T6) up to one-month postoperative. Methods: Surgical charts from January 2021 to October 2023 were reviewed for adult patients (≥18 years) who previously received a CNA0T2 to CNA0T6 (T2 to T6) IOL during uneventful cataract surgery and were targeted for emmetropia/first minus. Overall, charts from 193 eyes of 121 patients were screened, with 161 eyes of 107 patients included in the study. Data were collected from preoperative, and postoperative records up to approximately one-month (4-5 weeks), and included monocular corrected distance visual acuity (CDVA), uncorrected and distance-corrected intermediate visual acuity (UIVA and DCIVA), residual astigmatism, and absolute IOL rotation (measured from the axis position at the end of surgery up to one-month). Results: For the full cohort (T2 to T6 IOLs, n=161 eyes), CDVA was -0.01 ± 0.07 logMAR at one-month. Monocular UIVA was 0.22 ± 0.14 logMAR, DCIVA was 0.24 ± 0.12 logMAR, and absolute IOL rotation was 1.02 ± 1.21°. Residual astigmatism was very low (<0.01D) and consistently low across T2 to T6 IOLs. A T3 to T6 sub-analysis (n=64 eyes) found CDVA of -0.01 ± 0.07 logMAR, UIVA of 0.20 ± 0.14 logMAR, DCIVA of 0.23 ± 0.13 logMAR, and absolute rotation of 1.08 ± 1.26°. For all eyes, 1 serious ocular AE, cystoid macular edema, was identified. No serious non-ocular AEs, device deficiencies, or posterior capsular opacification were observed. Conclusion: The Clareon aspheric monofocal toric IOL showed excellent improvement in distance visual acuity and treatment of astigmatism, with functional intermediate visual acuity and minimal rotation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.